HIV protease inhibitor exposure predicts cerebral small vessel disease

AIDS

Volumn 28, Issue 9, 2014, Pages 1297-1306

  Soontornniyomkij, Virawudh ^a,b   Umlauf, Anya ^a   Chung, Sandra A ^a   Cochran, Megan L ^a   Soontornniyomkij, Benchawanna ^b   Gouaux, Ben ^a   Toperoff, Will ^a   Moore, David J ^a,b   Masliah, Eliezer ^a,c,d   Ellis, Ronald J ^a,d   Grant, Igor ^a,b   Achim, Cristian L ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Antiretroviral; Cognition; HIV dementia; Protease inhibitor; Small vessel disease

Indexed keywords

HEMOSIDERIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGED; AGING; ARTICLE; AUTOPSY; BRAIN BLOOD VESSEL; CEREBROVASCULAR DISEASE; COGNITION; COGNITION ASSESSMENT; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EXPOSURE; DYSLIPIDEMIA; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERTENSION; PRIORITY JOURNAL; SMOKING; UNITED STATES; VIRUS ENCEPHALITIS; WHITE MATTER; WHITE MATTER LESION; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPLICATION; HIV INFECTIONS; MALE; MIDDLE AGED;

ADULT; AGED; ANTI-HIV AGENTS; CALIFORNIA; CEREBRAL SMALL VESSEL DISEASES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED;

EID: 84922480904     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000262     Document Type: Article

References (58)

1. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 2008; 197 (Suppl 3):S294-S306.
2. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17:3-16.
3. Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, McArthur J. Evolution of HIV dementia with HIV infection. Int Rev Psychiatry 2008; 20:25-31.
4. Wiley CA, Achim C. Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome. Ann Neurol 1994; 36:673-676.
5. Cherner M, Masliah E, Ellis RJ, Marcotte TD, Moore DJ, Grant I, et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 2002; 59:1563-1567.
6. Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995; 38:755-762.
7. Anderson E, Zink W, Xiong H, Gendelman HE. HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr 2002; 31 (Suppl 2):S43-S54.
8. Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004; 18 (Suppl 1):S75-S78.
9. Cysique LA, Brew BJ. Prevalence of nonconfounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 2011; 17:176-183.
10. Grant I. Neurocognitive disturbances in HIV. Int Rev Psychiatry 2008; 20:33-47.
11. Everall I, Vaida F, Khanlou N, Lazzaretto D, Achim C, Letendre S, et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol 2009; 15:360-370.
12. Gelman BB, Chen T, Lisinicchia JG, Soukup VM, Carmical JR, Starkey JM, et al. The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS One 2012; 7:e46178.
13. Gelman BB, Lisinicchia JG, Morgello S, Masliah E, Commins D, Achim CL, et al. Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAARTera cohort. J Acquir Immune Defic Syndr 2013; 62:487-495.
14. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
15. Soontornniyomkij V, Achim CL. Aging. In: Gendelman HE. editor. The neurology of AIDS. New York: Oxford University Press; 2012. pp. 567-580.
16. Soontornniyomkij V, Moore DJ, Gouaux B, Soontornniyomkij B, Tatro ET, Umlauf A, et al. Cerebral b-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE e4 carriers. AIDS 2012; 26:2327-2335.
17. Cherner M, Letendre S, Heaton RK, Durelle J, Marquie-Beck J, Gragg B, et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005; 64:1343-1347.
18. Letendre SL, Cherner M, Ellis RJ, Marquie-Beck J, Gragg B, Marcotte T, et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 2005; 19 (Suppl 3):S72-S78.
19. Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US healthcare system. J Acquir Immune Defic Syndr 2012; 60:351-358.
20. Cruse B, Cysique LA, Markus R, Brew BJ. Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy. J Neurovirol 2012; 18:264-276.
21. Ortiz G, Koch S, Romano JG, Forteza AM, Rabinstein AA. Mechanisms of ischemic stroke in HIV-infected patients. Neurology 2007; 68:1257-1261.
22. Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in patients with HIV infection. Neurology 2011; 76:444-450.
23. Connor MD, Lammie GA, Bell JE, Warlow CP, Simmonds P, Brettle RD. Cerebral infarction in adult AIDS patients: observations from the Edinburgh HIV autopsy cohort. Stroke 2000; 31:2117-2126.
24. Rasmussen LD, Engsig FN, Christensen H, Gerstoft J, Kronborg G, Pedersen C, et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS 2011; 25:1637-1646.
25. Benjamin LA, Bryer A, Emsley HC, Khoo S, Solomon T, Connor MD. HIV infection and stroke: current perspectives and future directions. Lancet Neurol 2012; 11:878-890.
26. Singer EJ, Valdes-Sueiras M, Commins DL, Yong W, Carlson M. HIV stroke risk: evidence and implications. Ther Adv Chronic Dis 2013; 4:61-70.
27. Grunfeld C. Dyslipidemia and its treatment in HIV infection. Top HIV Med 2010; 18:112-118.
28. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-330.
29. d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004; 18:1811-1817.
30. Corral I, Quereda C, Moreno A, Pérez-Elías MJ, Dronda F, Casado JL, et al. Cerebrovascular ischemic events in HIV-1- infected patients receiving highly active antiretroviral therapy: incidence and risk factors. Cerebrovasc Dis 2009; 27:559-563.
31. Worm SW, Kamara DA, Reiss P, Fontas E, De Wit S, El-Sadr W, et al. Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. J Infect Dis 2012; 205:535-539.
32. McMurtray A, Nakamoto B, Shikuma C, Valcour V. Small-vessel vascular disease in human immunodeficiency virus infection: the Hawaii aging with HIV cohort study. Cerebrovasc Dis 2007; 24:236-241.
33. Ovbiagele B, Saver JL. Cerebral white matter hyperintensities on MRI: current concepts and therapeutic implications. Cerebrovasc Dis 2006; 22:83-90.
34. Archibald SL, Masliah E, Fennema-Notestine C, Marcotte TD, Ellis RJ, McCutchan JA, et al. Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol 2004; 61:369-376.
35. Miller RF, Lucas SB, Hall-Craggs MA, Brink NS, Scaravilli F, Chinn RJ, et al. Comparison of magnetic resonance imaging with neuropathological findings in the diagnosis of HIV and CMV associated CNS disease in AIDS. J Neurol Neurosurg Psychiatry 1997; 62:346-351.
36. Heindel WC, Jernigan TL, Archibald SL, Achim CL, Masliah E, Wiley CA. The relationship of quantitative brain magnetic resonance imaging measures to neuropathologic indexes of human immunodeficiency virus infection. Arch Neurol 1994; 51:1129-1135.
37. Filippi CG, Sze G, Farber SJ, Shahmanesh M, Selwyn PA. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology 1998; 206:491-498.
38. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5:347-360.
39. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001; 64:575-611.
40. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010; 120:287-296.
41. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 2010; 67:181-198.
42. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9:689-701.
43. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry 1996; 153:1195-1201.
44. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, et al. The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 1988; 45:1069-1077.
45. Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 2004; 26:759-778.
46. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69:1789-1799.
47. Deramecourt V, Slade JY, Oakley AE, Perry RH, Ince PG, Maurage CA, et al. Staging and natural history of cerebrovascular pathology in dementia. Neurology 2012; 78:1043-1050.
48. Anders KH, Guerra WF, Tomiyasu U, Verity MA, Vinters HV. The neuropathology of AIDS. UCLA experience and review. Am J Pathol 1986; 124:537-558.
49. Gray F, Gherardi R, Keohane C, Favolini M, Sobel A, Poirier J. Pathology of the central nervous system in 40 cases of acquired immune deficiency syndrome (AIDS). Neuropathol Appl Neurobiol 1988; 14:365-380.
50. Gelman BB, Rodriguez-Wolf MG, Wen J, Kumar S, Campbell GR, Herzog N. Siderotic cerebral macrophages in the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1992; 116:509-516.
51. Budka H. Neuropathology of human immunodeficiency virus infection. Brain Pathol 1991; 1:163-175.
52. Budka H, Wiley CA, Kleihues P, Artigas J, Asbury AK, Cho ES, et al. HIV-associated disease of the nervous system: review of nomenclature and proposal for neuropathology-based terminology. Brain Pathol 1991; 1:143-152.
53. Attems J, Jellinger K, Thal DR, Van Nostrand W. Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2011; 37:75-93.
54. Lefèvre C, Auclair M, Boccara F, Bastard JP, Capeau J, Vigouroux C, et al. Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin. Arterioscler Thromb Vasc Biol 2010; 30:2611-2620.
55. Giwa MO, Williams J, Elderfield K, Jiwa NS, Bridges LR, Kalaria RN, et al. Neuropathologic evidence of endothelial changes in cerebral small vessel disease. Neurology 2012; 78:167-174.
56. Eugenin EA, Morgello S, Klotman ME, Mosoian A, Lento PA, Berman JW, et al. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol 2008; 172:1100-1111.
57. Reyskens KM, Fisher TL, Schisler JC, O'Connor WG, Rogers AB, Willis MS, et al. Cardio-metabolic effects of HIV protease inhibitors (lopinavir/ritonavir). PLoS One 2013; 8:e73347.
58. Ragnauth CD, Warren DT, Liu Y, McNair R, Tajsic T, Figg N, et al. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010; 121:2200-2210.